Harmony Biosciences Holdings, I

Valuation Analysis

About the Company

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and othe

Harmony Biosciences Holdings, I Stock at a Glance

Harmony Biosciences Holdings, I (HRMY) is currently trading at $34.46 with a market capitalization of $2B. The trailing P/E ratio stands at 13.9x, with a forward P/E of 6.17x. The 52-week range spans from $25.52 to $40.87; the current price is 15.7% below the yearly high. Year-over-year revenue growth stands at +16.6%. The net profit margin stands at 16.2%.

💰 Dividend

Harmony Biosciences Holdings, I currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

11 analysts rate Harmony Biosciences Holdings, I (HRMY) on consensus: None. The average price target is $44.36, implying +28.74% from the current price. Analyst price targets range from $28.00 to $85.00.

Harmony Biosciences Holdings, I: The Investment Case in Detail

Harmony Biosciences Holdings, I (HRMY) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 16.6% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 76.55%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 16.2%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

The Bear Case

Short interest sits at 13.73% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

The EV/EBITDA multiple of 7.07x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 6.17x is meaningfully below the trailing 13.9x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 28.74% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (13.73%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Harmony Biosciences Holdings, I?

Compare top-rated brokers — low fees, trusted providers, fully regulated.